首页> 中文期刊> 《中外医疗》 >倍他乐克在糖尿病急性心肌梗塞中的临床应用

倍他乐克在糖尿病急性心肌梗塞中的临床应用

             

摘要

Objective To investigate the treatment of diabetes, acute myocardial infarction metoprolol clinical results. Methods In our hospital from January 2011 to January 2014 were treated 60 cases of acute myocardial infarction in patients with diabetes were randomly divided into two groups, the implementation of routine treatment, research group with metoprolol on this basis oral treat-ment, comparing the two groups. Results The deterioration of heart function, atrioventricular block, and no significant difference in the incidence of hypotension (P>0.05), but the mortality study, malignant arrhythmias and angina after infarction was significantly lower than the control group (P<0.05);after treatment, both groups were significantly lower blood glucose (P<0.05);and lipid lev-els before and after treatment were not significantly different (P> 0.05). Conclusion Metoprolol treatment of diabetic patients with acute myocardial infarction, can significantly reduce the mortality and incidence of malignant arrhythmias and angina, heart func-tion but did not change significantly, but no significant impact blood sugar, blood lipids.%目的:探讨倍他乐克治疗糖尿病急性心肌梗塞的临床效果。方法选取该院在2011年1月—2014年1月收治的急性心肌梗死合并糖尿病患者60例,随机分为两组,对照组实施常规治疗,研究组在此基础上加用倍他乐克口服治疗,比较两组疗效。结果两组心功能恶化、房室传导阻滞和低血压发生率差异无统计学意义(P>0.05),但研究组死亡率、恶性心律失常和梗死后心绞痛发生率均明显小于对照组(P<0.05);两组治疗后的血糖均明显降低(P<0.05);且两组治疗前后血脂变化均差异无统计学意义(P>0.05)。结论倍他乐克治疗糖尿病合并急性心肌梗死,可明显降低患者死亡率以及恶性心律失常和心绞痛的发生率,但对心功能变化不明显,同时血糖、血脂无较大影响。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号